Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness of satralizumab, inebilizumab, and mycophenolate mofetil in AQP4-IgG-positive NMOSD
ChiCTR2600128384Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of satralizumab, inebilizumab and mycophenolate mofetil in neuromyelitis optica spectrum disorder (NMOSD) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: time to first protocol-defined relapse, disability progression and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
satralizumabinebilizumabmycophenolate mofetil
03
Conditions
neuromyelitis optica spectrum disorder (NMOSD)
Beyond the preview
Go deeper on ChiCTR2600128384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128384.